Teva Pharmaceuticals Presents Promising New Data for Schizophrenia Treatments
San Diego, CA – September 21, 2025 – Teva Pharmaceuticals today announced encouraging findings from its schizophrenia medication portfolio presented at the 2025 Psych Congress Annual Meeting in San Diego. The data highlights potential advancements in both safety and patient care for individuals living with this complex mental health condition.
Key findings include long-term safety data from the completed Phase 3 SOLARIS trial evaluating olanzapine LAI (TEV-‘749), a novel once-monthly, long-acting injectable (LAI) subcutaneous formulation of olanzapine. Notably,the trial demonstrated no incidence of post-injection delirium/sedation syndrome (PDSS) among participants. This is a meaningful finding, as PDSS can be a concerning side effect with some antipsychotic medications. Olanzapine LAI represents a potential first-of-its-kind long-acting olanzapine treatment option.
In addition, new data on UZEDY®, a risperidone extended-release injectable suspension administered subcutaneously every one to two months, showed a statistically significant association with a shorter length of hospitalization compared to patients receiving a once-monthly intramuscular injection of Invega Sustenna®. It’s significant to note that this analysis did not evaluate efficacy, safety, or other clinical outcomes - only length of hospital stay.
“These presentations underscore Teva’s commitment to developing innovative treatment options for individuals with schizophrenia,” said a Teva spokesperson.”We are encouraged by these findings and believe they represent a step forward in improving the lives of patients.”
The data presented at Psych Congress builds on Teva’s ongoing research into long-acting injectable antipsychotics, which aim to improve medication adherence and overall patient outcomes.
SEO Considerations:
